Lumen Bioscience said that it has received a contract worth $8.8 million from the Defense Innovation Unit (DIU) of the US Department of Defense for development of "a prototype broad-spectrum, fast-acting intranasal powder for treatment and prevention of known and emerging viral respiratory infections." The funding is part of "Project Panacea," run by DIU and the Joint … [Read more...] about Lumen Bioscience to develop antiviral intranasal powder for US Department of Defense
Business
Chance Pharmaceuticals acquires rights to distribute Inbrija levodopa DPI in China
Hangzhou Chance Pharmaceuticals will pay Acorda Therapeutics $2.5 million up front for distribution rights to Inbrija levodopa DPI in China plus another $6 million in "a near term milestone payment" as well as $3 million on approval and as much as $132.5 million in sales milestones. Chance will also pay by the carton for Acorda to supply Inbrija to the company. Acorda … [Read more...] about Chance Pharmaceuticals acquires rights to distribute Inbrija levodopa DPI in China
Strides and Orbicular partner on development of nasal sprays
Generics manufacturer Strides Pharma Science and CRO Orbicular Pharmaceutical Technologies, both based in India, have announced a new strategic partnership where Orbicular will formulate 4 nasal sprays to be manufactured and commercialized by Strides. According to the announcement, Strides will manufacture the nasal sprays at its facility in Chestnut Ridge, NY, USA … [Read more...] about Strides and Orbicular partner on development of nasal sprays
Bausch Health launches Ryaltris olopatadine / mometasone furoate nasal spray in Canada
Bausch Health has announced the launch of Ryaltris olopatadine / mometasone furoate nasal spray for in Canada. Bausch Health acquired the Canadian rights to Ryaltris from Glenmark in March 2021, and Health Canada approved the nasal spray for the treatment of moderate to severe seasonal allergic rhinitis in September 2022. Ryaltris was approved by the FDA in … [Read more...] about Bausch Health launches Ryaltris olopatadine / mometasone furoate nasal spray in Canada
Huro Biotech gets manufacturing rights for Destiny Pharma and SporeGen’s SPOR-COV bacillus nasal spray
Destiny Pharma and SporeGen have announced that Vietnamese biotechnology company Huro Biotech has acquired non-exclusive manufacturing rights for SPOR-COV bacillus nasal spray as well as exclusive marketing rights to the nasal spray in Vietnam. Huro has also launched an OTC nasal spray in Vietnam based on SPOR-COV technology, the companies said. In September 2020, … [Read more...] about Huro Biotech gets manufacturing rights for Destiny Pharma and SporeGen’s SPOR-COV bacillus nasal spray
Amphastar acquires Baqsimi intranasal dry powder glucagon from Lilly
Amphastar Pharmaceuticals will pay Eli Lilly $500 million up front, an additional $125 million after one year, and up to $450 million in sales milestone payments for the rights to Baqsimi intranasal dry powder glucagon. The company says that the product is currently marketed in 27 countries. Baqsimi was approved by the FDA in July 2019 for the emergency treatment of … [Read more...] about Amphastar acquires Baqsimi intranasal dry powder glucagon from Lilly
Ritedose begins manufacturing 0.5% albuterol sulfate inhalation solution ampules
Ritedose Corporation, which says that it is the largest manufacturer of albuterol sulfate inhalation solution in the US, announced that it has begun compounding 5 mg/ml albuterol sulfate inhalation solution ampules through the 503B manufacturing process in response to a shortage, with shipping directly to hospitals expected to begin in May of this year. The … [Read more...] about Ritedose begins manufacturing 0.5% albuterol sulfate inhalation solution ampules
Satsuma Pharmaceuticals and its STS101 DHE nasal powder to be reacquired by SNBL
Satsuma Pharmaceuticals, which was spun out of Shin Nippon Biomedical Laboratories (SNBL) over 6 years ago to develop an intranasal dry powder formulation of dihydroergotamine, has announced that it will now be acquired by SNBL. Satsuma recently said that it had submitted an NDA for STS101 DHE nasal powder for the treatment of migraine despite the failure of the Phase … [Read more...] about Satsuma Pharmaceuticals and its STS101 DHE nasal powder to be reacquired by SNBL
Aer Therapeutics closes $36 million financing to support development of AER-01 inhaled mucolytic for COPD
University of California, San Francisco spinout Aer Therapeutics has closed a $36 million Series A financing, with funds intended to support development of the company's AER-01 inhaled mucolytic for the treatment of COPD, the company said. According to the announcement, AER-01 is a thiol-saccharide designed to dissolve mucus plugs and was developed at UCSF in … [Read more...] about Aer Therapeutics closes $36 million financing to support development of AER-01 inhaled mucolytic for COPD
Tiziana says it will develop intranasal foralumab for the treatment of long COVID
Tiziana Life Sciences has announced that the company will develop intranasal foralumab for the treatment of long COVID. In August 2021, Tiziana announced positive results from a pilot study of intranasal foralumab in mild-to-moderate COVID. The nasal formulation is currently in development for the treatment of non-active secondary progressive multiple sclerosis, and … [Read more...] about Tiziana says it will develop intranasal foralumab for the treatment of long COVID